REVEAL is a randomized trial investigating the effects of adding anacetrapib (a potent CETP inhibitor) to effective LDL-lowering treatment with atorvastatin. Over 30,000 participants with pre-existing atherosclerotic vascular disease have been randomized between anacetrapib 100 mg daily versus matching placebo, , along with active atorvastatin. Follow-up is scheduled to continue for a median of about 4 years. The primary aim is to assess the effect of anacetrapib on the composite outcome of major coronary event, defined as coronary death, myocardial infarction or coronary revascularization. Secondary aims include assessment of the safety of anacetrapib, as well as the effects on a number of other outcomes.

Recruitment of over 30,000 study participants was completed between 2011 and 2013.

Results are anticipated in 2017.

The trial is coordinated at CTSU, with academic collaborators leading regional coordinating centres in Europe, North America and China. The University of Oxford is the trial Sponsor. Financial support has been provided by Merck Sharp & Dohme.

ClinicalTrials.gov Identifier: NCT01252953 

ISRCTN: 48678192

Our team

  • Martin Landray
    Martin Landray

    Professor of Medicine and Epidemiology; Deputy Director, Big Data Institute

  • Louise Bowman
    Louise Bowman

    Associate Professor of Clinical Trials and Epidemiology & Honorary Consultant Physician (Lipidology)

  • Rory Collins
    Rory Collins

    Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology

Funding

Unrestricted grant from Merck, Sharp and Dohne (see Unit's funding policy here)

Related research themes